Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
A happy couple who first met seven years ago when they both awoke from comas got engaged inside the same hospital where they were treated as teenagers. Zach Zarembinski popped the question to Isabelle ...
– Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...
Senate Majority Leader John Thune (R-S.D.) is set to hold a vote Friday with an eye toward ending the government shutdown. The GOP leader told lawmakers over a conference lunch that he will hold ...
SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...
The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...
Scientists have uncovered a hidden weakness in one of the deadliest childhood cancers. The tumors, which spread quickly and are notoriously hard to treat, rely on a sugar-processing pathway to survive ...
Health tech company Doximity bought Pathway Medical to bulk up its healthcare artificial intelligence capabilities as it looks to offer more free AI tools to doctors. The transaction closed July 29 ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile. Freimer was an author on 5 abstracts presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results